The effects of oral glucosamine on joint health: is a change in research approach needed?
| Autor: | Anna Plaas, Joel A. Block, John D. Sandy, Theodore R. Oegema |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Biomedical Engineering
Administration Oral Pain Context (language use) Osteoarthritis Therapeutics Pharmacology Placebo chemistry.chemical_compound Dogs Rheumatology Glucosamine Medicine Animals Humans Orthopedics and Sports Medicine Horses Disease management (health) Inflammation Hexosamine metabolism business.industry Therapeutic effect Outcome measures medicine.disease Rats Clinical trial carbohydrates (lipids) Cartilage chemistry Cattle Joints lipids (amino acids peptides and proteins) Rabbits business |
| Zdroj: | Osteoarthritis and Cartilage. 18(1):5-11 |
| ISSN: | 1063-4584 |
| DOI: | 10.1016/j.joca.2009.07.005 |
| Popis: | Summary Objective Oral glucosamine (GlcN) has been widely studied for its potential therapeutic benefits in alleviating the pain and disability of osteoarthritis (OA). Its popularity has grown despite ongoing controversy regarding its effectiveness vs placebo in clinical trials, and lack of information regarding possible mechanisms of action. Here, we review the state of knowledge concerning the biology of GlcN as it relates to OA, and discuss a framework for future research directions. Methods An editorial "narrative" review of peer-reviewed publications is organized into four topics (1) Chemistry and pharmacokinetics of GlcN salts (2) Biological effects of GlcN salts in vitro (3) Therapeutic effects of GlcN salts in animal models of OA and (4) GlcN salts in the treatment of clinical OA. Results Data reporting potent pleiotropic activities of GlcN in in vitro cell and explant cultures are discussed in the context of the established pharmacokinetic data in humans and animals. The available clinical trial data are discussed to place the patient in the context of controlled research on disease management. Conclusions Future research to determine therapeutic mechanisms of GlcN salt preparations will require use of standardized and clinically relevant in vitro assay systems and in vivo animal models for testing, as well as development of new outcome measures for inflammation and pain pathways in human OA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect